Nuvation Bio 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- Nuvation Bio reported 3rd quarter 2026 total revenue of $45 million, including $27.5 million in net U.S. iptrozi product revenue and $17.5 million in collaboration and license revenue.
- For the first 9 months of 2026, total revenue was $159.9 million, including $69.2 million in net U.S. iptrozi product revenue and $90.7 million in collaboration and license revenue.
- Iptrozi net U.S. product revenue grew 18% sequentially, and approximately 160 new patients started treatment, about 65% of them in the first-line setting.
- Iptrozi had more than 60% share of first-line new patient starts and was the leading ROS1 TKI in total active patients across all lines of therapy at quarter-end.
- The company reported total operating expenses of $75.2 million for the quarter, including R&D expenses of $32.7 million and SG&A expenses of $42.6 million.
- Cash, cash equivalents, and marketable securities totaled $663.4 million as of September 30th, 2026.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Hello, and welcome to Nuvation Bio's third quarter 2026 financial results and business update call. Today's call is being recorded, and a replay will be available on the company's website. All participants are currently in a listen-only mode. A brief question-and-answer session will follow the prepared remarks. Now, I'd like to turn the call over to J.R. DeVita, Vice President of Corporate Development and Investor Relations at Nuvation Bio.
Please go ahead. Thank you, and good afternoon, everyone.
Earlier today, we issued a press release summarizing our financial results for the quarter ending September 30, 2026, and provided a business update. The press release is available on the investors section of our website at nuvationbio.com. Today's call includes forward-looking statements, including statements about the therapeutic and commercial potential of IBTROZI and safusidenib, our development plans for taletrectinib, safusidenib, and our drug-drug conjugate platform, along with our plans for future updates from these programs, the components of our anticipated product revenue, our expected milestone payments and spending patterns, and our cash runway and profitability potential. Because such statements deal with future events and are subject to many risks and uncertainties, actual results may differ materially from those in the forward-looking statements.
For a full discussion of these risks and uncertainties, please review our quarterly report on Form 10-Q, which we filed with the U.S. Securities and Exchange Commission today. Joining me on today's call are our Founder, President, and Chief Executive Officer, Dr. David Hung, our Chief Commercial Officer, Colleen Sjogren, and our Chief Financial Officer, Philippe Sauvage. Now I'll turn the call over to Dr. David Hung.
David, please go ahead. Thanks, J.R. Good afternoon, everyone, and thank you all for joining us.
Today, I'm pleased to discuss the progress we made across our business in the third quarter. We generated $45 million in overall revenue, driven by another quarter of strong IBTROZI growth. Net U.S. IBTROZI product revenue was $27.5 million, which represented 18% growth from the last quarter. Approximately 160 new patients started treatment with IBTROZI, about 65% of which were in the first-line setting. The commercial signals that matter most to our long-term thesis remain encouraging. 15 months into our U.S. launch, we continue to both build a growing base of patients on therapy and strengthen our position in the ROS1 market.
IBTROZI has reached an all-time high in its share of active patients receiving a ROS1 TKI and continues to lead in first-line new patient starts with greater than 60% market share as of the end of the quarter. Our revenue growth reflects an expanding active treatment base driven by an increasing proportion of first-line patients that we believe can stay on therapy for years, as seen in our TRUST clinical studies. IQVIA claims data from the third quarter demonstrated a 15% decline in total new patient starts across the ROS1 TKI market. This is further evidenced by a lower volume of ROS1-positive testing alerts from our laboratory data partners. We believe these observations suggest that at least part of the softness in our first-line new patient starts is a reflection of the overall flow of newly identified and treated patients, rather than a loss of IBTROZI's competitive position.
Despite the market dynamics described, as of the end of the quarter, we maintain our strong position as the leading ROS1 TKI in total active patients across all lines of therapy combined. ROS1-positive lung cancer is an ultra-rare disease, and the number of new patients entering treatment can fluctuate from quarter to quarter. We do not believe one quarter provides sufficient data to establish an identifiable demand trend nor draw clear conclusions. We are monitoring market activity and treatment patterns closely while maintaining our focus on the drivers we can influence: identifying patients earlier, educating physicians about appropriate testing, supporting biomarker-informed treatment decisions, and increasing appropriate use of targeted therapy. We also are encouraged by how IBTROZI's launch compares with historical targeted lung cancer launches, particularly given the small ROS1 population and fragmented prescriber base.
While we realize comparisons are nuanced due to differences in size of patient populations, cost of therapy, and initially approved lines of therapy, we believe this is helpful to put IBTROZI's launch in context. For example, five full quarters into the launches of LORBRENA and ALECENSA for ALK-positive lung cancer, U.S. net revenues per SEC filings and financial reports were $25 million and $36 million respectively. As you know, IBTROZI has already reached similar levels of sales in a more competitive market despite ROS1 incidence being approximately half that of ALK. It is key to remember that the ALK-positive lung cancer market was not developed overnight. It took time for testing patterns, physician confidence, durability on treatment, and long-term data to align behind the agents that ultimately became market leaders today. Most fundamentally, our confidence begins with the clinical profile.
In TKI-naive patients in TRUST-I, IBTROZI demonstrated a 90% objective response rate, or ORR, 15 months of median duration of response, or DOR, and 15 months of median progression-free survival, or PFS. Its tolerability profile, including the unique absence of a CNS warning and precaution in the label, is another critical point of differentiation among brain-penetrant ROS1 TKIs. And remember, these metrics are supported by median patient follow-up of 51 months in the TRUST-I study. We believe these attributes can support physician confidence, sustained first-line adoption, and meaningful time on therapy. This clinical profile is also one of the reasons we chose to develop IBTROZI in the adjuvant setting, where we're encouraged that enrollment is fully on track in this first-of-its-kind study for ROS1.
If approved, this indication could expand the patient population IBTROZI is able to address, and the data from Eli Lilly's LIBRETTO study in RET-positive non-small cell lung cancer has given us even more confidence that we could reach a meaningful result in ROS1 sooner than we initially thought. Taken together, the results reinforce our view that we are building a durable commercial franchise and that IBTROZI has become the standard of care in ROS1-positive lung cancer. Quarterly new patient activity will not always move in a straight line, but our competitive positioning, growing active patient base, and ability to reach more eligible patients provide a strong foundation for the years ahead. Moving to safusidenib, we remain very excited about this program and its potential to become a key value driver for Nuvation Bio as we move to 2027 and beyond.
In August, the FDA granted Fast Track designation to safusidenib for the treatment of IDH1 mutant glioma. We view this as supportive external validation of both the unmet need in this disease and the potential development path for safusidenib. Fast Track designation is intended to facilitate development and expedite review of therapies that may address serious conditions with unmet medical need, and we are pleased to have this designation as we continue to advance the program. As a reminder, in July, we announced updated long-term results from the phase II J201 study in 27 patients with chemotherapy and radiotherapy-naive grade 2 IDH1 mutant glioma. With a median follow-up of 39 months, the centrally assessed ORR increased to 52% from 44% at 28 months of median follow-up. Median PFS had not yet been reached, and the 36-month PFS rate was 79%.
Responses in the study have continued to deepen, and no new safety signals were observed with additional follow-up. We will present more detailed data beyond these top-line results at the Society for Neuro-Oncology Annual Meeting next week. As a result of this encouraging dataset, we recently announced an enhanced development plan that allows us to address two key goals. First, our four studies together address all grades and risk groups within the broad IDH1 mutant glioma landscape. Second, two of these studies focus on patient groups with high unmet needs and no alternative treatment options and evaluate ORR as a primary endpoint, which will allow us to generate data quickly.
In fact, these two studies in patients with grade 3 oligodendroglioma and in patients who have progressed following treatment with vorasidenib also analyze tumor growth rate, or TGR, as a secondary endpoint, which may provide an even earlier signal of efficacy. This is a key difference from our other two pivotal randomized studies, which evaluate PFS as a primary endpoint and will not generate data until 2029 or later. As a reminder, these pivotal studies include SIGMA, which is evaluating safusidenib in patients with high-grade and high-risk astrocytoma, and a separate study in patients with grade 2 IDH1 mutant glioma. Enrollment in the SIGMA study, including the exploratory cohort, is on track, and we expect to be enrolling patients in all four studies in the coming months. We plan to provide more specific updates on enrollment and clarity around timing of data readouts next year.
Finally, we also remain on track to provide an update on our drug-drug conjugate, or DDC platform, by the end of the year. This update will include additional detail on how we plan to move the program forward and into the clinic. We are excited by the progress of this program and look forward to sharing more information soon. Overall, the third quarter reinforced the long-term opportunity in front of us. IBTROZI is now a commercial leader with a growing active patient base that is driven by an increasing number of new first-line patients and their long duration of treatment. Safusidenib continues to advance as a meaningful second franchise with potential data next year, and our DDC platform could contribute to future pipeline growth. With that, I will turn the call over to Colleen to provide a more detailed update on IBTROZI's commercial launch.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
17 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
